A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
about
HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinomaDifferential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.Immunomic analysis of human sarcomaTreatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1Sp17 gene expression in myeloma cells is regulated by promoter methylationNY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimensSurvey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responsesIdentification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phageA simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteinsStem cells and targeted approaches to melanoma cureMonitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodiesAntigen-specific immunotherapy of cervical and ovarian cancerYeast homolog of a cancer-testis antigen defines a new transcription complex.Immunotherapy for Bone and Soft Tissue SarcomasImmunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesCancer/testis antigens: an expanding family of targets for cancer immunotherapyCancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomasHuman Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune responsePre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapyA novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapyVaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patientsProfiling the immune response in patients with breast cancer by phage-displayed cDNA libraries.CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemiaAberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients.Using protein microarray as a diagnostic assay for non-small cell lung cancerAnalysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica.CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.Evidence for a bias toward intracellular antigens in the local humoral anti-tumor immune response of a colorectal cancer patient revealed by phage display.Molecular characterization of virus-induced autoantibody responses.De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma.PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus.Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer.The sentinel within: exploiting the immune system for cancer biomarkers.Identification of tumor associated antigens recognized by IgG from tumor-infiltrating B cells of lung cancer: correlation between Ab titer of the patient's sera and the clinical course.Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer.Peptides from the variable region of specific antibodies are shared among lung cancer patients.
P2860
Q24315946-25C821DA-D139-400E-B3C9-AE3AB84AA2C3Q24533572-AEF7A3DC-7299-4D2B-933E-537387F871DEQ24554211-16AD00C9-0A77-432F-BF25-B6D45E9179E2Q24633445-2CAB66FD-A29C-42FA-A760-BB71364A8015Q24645368-6B407C5F-71C1-42AD-B5B9-F4121240A182Q24649090-7A4D31F7-428C-402C-8870-BC67F431EA2AQ24678759-E142A6E9-1FE7-4903-BD8D-30ECAF6FAD98Q24809683-D9238944-32D3-4E64-9A31-48C4C1E6BF38Q24813048-3CB261CA-D743-4715-AE34-254673DDA1B5Q26825014-9BC0A34B-6315-43EF-8CA5-3854B0639132Q27345217-D220A31C-4067-4BF4-BF03-F52F174AF1DCQ27488697-2B274D20-CBB6-4404-87A1-5770D9428866Q27933400-8925AF3D-D2B0-484A-80F6-2E995147349EQ28088363-F2E0DF73-C937-4D09-B5C3-DE014BEBEEFEQ28188712-A855B8DF-B41A-47A2-8F82-B2CF29EB2680Q28215652-D42E7436-E4D1-466D-8B34-DF9B2E532265Q28220657-824BE3E1-D65B-4785-8D52-1DF30B3566A6Q28251022-2CFF33A2-8550-4039-8A26-5438EA1DFAC3Q28344557-F430DB3A-54EA-42C4-8E42-43FBECCB9533Q28709361-039A0642-766B-4077-A1B1-41C0284EBF56Q30299957-0C5B398B-B29F-4748-9B1F-B2E98886B803Q30358114-E78C3387-0D39-4120-9A07-C3EDABDC17DDQ30657549-69E3F612-B83E-4A16-A45A-147DA777D2E3Q30679410-D0214017-C990-49A8-B158-EC17DC31FAC4Q30713843-11600214-6BDF-42BC-8851-3CA6F43CDCD4Q30785776-D98A1124-F69F-4A17-A663-5B168D559438Q30796772-1E40C081-A87F-488C-9CCD-AFA35A236360Q30822552-5F97B95B-1644-49EC-BF12-F00D2C353C70Q30859024-34A13240-F540-4E98-B1C8-2F7D2B03A9EBQ31004523-0814E20F-49BF-4CB0-BBCF-559158EE0A0CQ31110185-988EE77C-8F35-41DA-96D8-281ED524AF21Q31938591-AAAA1919-0716-4ABF-A36C-6364C304FAFEQ32028600-66AC6946-686C-4FE9-96D1-1FD61183F48AQ32061664-D29919E0-FACD-4600-A422-3A44557F4537Q33195347-FCD11530-EBFC-4CD0-9169-3ADC4F479BECQ33214731-FCF53C03-78F9-4993-BD13-D193C88463DDQ33221191-AD0C6E54-2124-44D1-85B7-12D5B0345321Q33230009-3DDC3B6A-92ED-40F8-B838-5FC14BF7E414Q33432974-3C67453B-49DA-46BB-A20C-A9E13D054CD2Q33553735-4B3F843E-66FB-4303-90F0-8BABF2AF0568
P2860
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
A survey of the humoral immune ...... panel of human tumor antigens.
@ast
A survey of the humoral immune ...... panel of human tumor antigens.
@en
type
label
A survey of the humoral immune ...... panel of human tumor antigens.
@ast
A survey of the humoral immune ...... panel of human tumor antigens.
@en
prefLabel
A survey of the humoral immune ...... panel of human tumor antigens.
@ast
A survey of the humoral immune ...... panel of human tumor antigens.
@en
P2093
P2860
P356
P1476
A survey of the humoral immune ...... panel of human tumor antigens.
@en
P2093
E Stockert
M J Scanlan
P2860
P304
P356
10.1084/JEM.187.8.1349
P407
P577
1998-04-01T00:00:00Z